• Skip to primary navigation
  • Skip to content
  • Skip to footer navigation
Aucta Pharma

Aucta Pharma

  • About Aucta
  • Strategy
  • Product Portfolio
  • Therapeutic Area
  • Investors
  • Contact Us
  • English
    • 简体中文
  • Therapeutic Area
  • Central Nervous System
  • Dermatology
  • Pediatrics

UAP006

UAP006, an mTOR inhibitor currently approved as oral immunosuppressant agent indicated for the prophylaxis of organ rejection in patients receiving renal transplants, is being developed by Aucta for a new derm indication, i.e. TSC related facial angiofibromas. Aucta has obtained orphan drug designation on this product and the program is currently undergoing Ph2 clinical study in U.S. and later on other countries.

AUC029

AUC029, a non-selective beta-adrenergic receptor blocking agent indicated in the treatment of elevated intraocular pressure in patients with ocular hypertension or open-angle glaucoma, is being developed by Aucta for a new derm indication, i.e. infant hemangioma. Aucta has obtained CTA approval from CFDA on this product and the program is currently undergoing clinical studies in China.

We have expertise in a number of topical dosage forms, including ointment, gel, foam and spray. Topical form presents an attractive segment for new drug devleopment as it has a much longer life cycle than other dosage forms due to difficult to copy nature of the product, i.e. clinical end point study is generally requied for generic copies.

  • About Aucta
  • Strategy
  • Product Portfolio
  • Therapeutic Area
  • Investors
  • Contact Us
  • English
Powered by Points Group • Privacy Policy •